Tirzepatide for treating type 2 diabetes – guidance (TA924)

NICE recommends tirzepatide for type 2 diabetes in adults, only if triple therapy with metformin and 2 other oral antidiabetic agents is ineffective, not tolerated or contraindicated, and other specific weight related risk factors and patient parameters apply.

SPS commentary:

NICE restrict use to patients:

  • With a BMI of 35 kg/m2 or more, with specific psychological or other medical problems associated with obesity, or
  • With a BMI of less than 35 kg/m2, and insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related complications.

Lower BMI thresholds (usually reduced by 2.5 kg/m2) should be used for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.

National Institute for Health and Care Excellence